Discover why Lyell Immunopharma (LYEL) stock is up 191% YTD. Explore CAR T therapy breakthroughs, trial milestones, and key investment insights.

Jasmine Ramirez will spend Christmas in the hospital after doctors worked nearly 17 hours to amputate her left leg. The surgery was successful, announced Ramirez’s sister, Anastashia Carrasquillo. “My ...

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

Miami Hurricanes basketball player Marcus Allen is out for the year after being diagnosed with non-Hodgkin lymphoma -- a form ...

Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets ...

Full House' alum Dave Coulier spoke exclusively with Parade about nearing the end of his second cancer treatment and the New ...

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous (SC) formulation for the treatment of adult ...

At the recent American Society of Hematology (ASH) annual meeting, phase II data were presented on a bispecific antibody for ...

Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.

At the recent American Society of Hematology annual meeting, real-world analyses examined how polatuzumab vedotin (Polivy) ...